XLRN - Merck says HSR waiting period for Acceleron Pharma deal expires

Merck (NYSE:MRK) said that the HSR waiting period for its planned purchase of Acceleron Pharma (NASDAQ:XLRN) has expired.  Acceleron rose 3.2% in premarket trading. Merck is extending its tender offer for Acceleron (XLRN) until Nov. 18, according to a statement. Merck (MRK) late last month withdrew its XLRN filing to allow the FTC more time to review the combination. The pharma giant agreed to buy Acceleron (XLRN) for more than $11B in cash, or $180/share in late September.  The deal has seen some opposition from holders who argue that the deal undervalued Acceleron.

For further details see:

Merck says HSR waiting period for Acceleron Pharma deal expires